The company says the personal example set by the PM will give a huge boost to the immunization campaign against the pandemic and help reduce vaccine hesitancy
March 1, 2021 – Bharat Biotech International Limited (BBIL), India’s leading vaccines and bio-therapeutics manufacturer, has welcomed the gesture of Hon’ble Prime Minister Sh. Narendra Modi in taking the first dose of Covid-19 vaccine himself.
Said Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech International Limited: “We thank the Hon’ble Prime Minister Sh. Narendra Modi for taking the first dose of COVID-19 vaccine himself and are deeply appreciative of the gesture. This has set a powerful example for all Indians to follow, which will go a long way in reducing vaccine hesitancy and building confidence in immunization against the ongoing pandemic. We express our sincere gratitude to the Hon’ble Prime Minister for reposing his trust in the indigenously developed COVID-19 vaccine, COVAXIN®️. We urge all fellow citizens to not hesitate from taking part in the Covid-19 immunization program so that the country can bring an end to this public health crisis.”
BBV152 (COVAXIN®️) contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. The vaccine is stable at +2°C to +8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.
About Bharat Biotech
Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.
Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public private partnerships resulted in the introduction of path breaking WHO pre-qualified vaccines BIOPOLIO®️, ROTAVAC®️ and Typbar TCV®️ combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the largest rabies vaccine manufacturer in the world. To learn more about Bharat Biotech visit www.bhar
atbiotech.com
